What is Accelagen?
Accelagen operates as a specialized Gene-to-Protein enterprise, providing critical infrastructure for the pharmaceutical and biotechnology industries. By leveraging advanced platforms such as the Baculovirus Expression Vector System, E. coli, and mammalian expression systems, the company delivers high-quality protein reagents essential for structural biology and therapeutic development. Their market position is defined by a commitment to technical precision in the production of antibodies and GPCRs, serving as a vital partner for organizations engaged in complex drug discovery pipelines. Through a combination of cost-effective methodologies and rigorous quality control, Accelagen has established itself as a reliable provider of recombinant protein expression and custom purification services.
How much funding has Accelagen raised?
Accelagen has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Accelagen
PPP
Public-Private Partnership
What's next for Accelagen?
The recent influx of capital is expected to accelerate Accelagen's operational capacity and technological reach. As the company transitions through this late-stage growth phase, strategic priorities will likely include the expansion of its proprietary expression platforms and the scaling of its custom purification services to meet rising global demand. By optimizing its technical workflows, Accelagen is well-positioned to capture additional market share in the therapeutic protein sector. Future initiatives will likely focus on enhancing throughput for high-complexity projects, ensuring the firm remains at the forefront of the bioprocessing landscape while maintaining the technical excellence that defines its current service offerings.
See full Accelagen company page
